drugset / Trial / NCT04196868
Methotrexate and Metformin in Rheumatoid Arthritis Patients
Phase 2
Completed
128 enrolled
University Hospital, Bordeaux
Ministry for Health and Solidarity, France · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Methotrexate (MTX) is the anchor drug for patients with rheumatoid arthritis (RA). Despite its marked efficacy and acceptable side effect profile, about 1/3 of patients failed to reach RA remission. Metformin is the first-line therapy for type 2 diabetes. Its antioxidative and anti-inflammatory properties make it a good candidate for the treatment of inflammatory diseases such as rheumatoid arthritis.
Timeline
- Start
- 2020-12-03
- Primary completion
- 2024-12-19
- Completion
- 2026-06-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 1500 mg | Oral |
| Background | Methotrexate | Small molecule | — | Oral |